Atea Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference
November 25 2020 - 7:00AM
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a
clinical-stage biopharmaceutical company focused on discovering,
developing and commercializing antiviral therapeutics to improve
the lives of patients suffering from life-threatening viral
infections, today announced that management will participate in a
fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference
on Thursday, December 3, 2020 at 12:35 p.m. ET.
A live webcast of the presentation will be available on the
Company’s website at www.ateapharma.com. A replay of the webcast
will be available for 90 days following the presentation.
About Atea Pharmaceuticals
Atea Pharmaceuticals is a clinical stage biopharmaceutical
company focused on discovering, developing and commercializing
therapies to address the unmet medical needs of patients with
life-threatening viral diseases. Leveraging the Company’s deep
understanding of antiviral drug development, nucleoside biology,
and medicinal chemistry, Atea has built a proprietary nucleotide
and nucleoside prodrug platform to develop novel product candidates
to treat single stranded ribonucleic acid, or ssRNA, viruses, which
are a prevalent cause of severe viral diseases. Currently, Atea is
focused on the development of orally- available, potent, and
selective purine nucleotide and nucleoside prodrugs for
difficult-to-treat, life-threatening viral infections, including
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
virus that causes COVID-19, hepatitis C virus (HCV) infection,
dengue virus, and respiratory syncytial virus (RSV). For more
information, please visit www.ateapharma.com.
Contacts
Investors:Will O’ConnorStern Investor Relations
212-362-1200will.oconnor@sternir.com
Media:Carol Guaccero301-606-4722contactus@ateapharma.com
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Apr 2023 to Apr 2024